One substance - one assessment (OSOA): EU collaboration on chemicals-related data

Information on EMA's role in helping implement the One substance - one assessment (OSOA) framework. This framework aims to improve coordination, efficiency and transparency of chemical safety assessments in Europe.
HumanVeterinary

This content applies to both human and veterinary medicines

'One substance – one assessment' (OSOA) refers to a legislative framework of the European Union (EU) designed to enable more coordinated, efficient and transparent chemical safety assessments.

Its overarching aim is to protect people living in the EU and their environment, while recognising the essential role chemicals play in everyday life. 

The framework aims to:

  • facilitate shared access to reliable, high-quality data among relevant authorities
  • strengthen scientific cooperation on chemicals
  • improve the EU’s ability to anticipate and manage chemical risks

OSOA applies to a wide range of products regulated at EU level, including biocides, pesticides, food and toys.

The legislative framework entered into force on 1 January 2026.

For more information on EMA's partners and networks, see:

Common data platform

A central element of the OSOA framework is establishing a new common data platform on chemicals used in the EU under Regulation (EU) 2025/2455

The aim is to support close cooperation and systematic data sharing between EU bodies involved in chemical safety assessments.

The European Chemicals Agency (ECHA) will manage this data platform with support from EMA and three other EU agencies involved in chemical safety assessments. These are the European Food Safety Authority (EFSA), the European Environment Agency (EEA), and the European Agency for Safety and Health at Work (EU-OSHA).

The data platform is expected to be operational in 2029.

EMA role

EMA will contribute data to the common data platform established under the OSOA legislative framework.

To ECHA, EMA will submit safety data on chemicals that are active substances of certain medicines defined in the framework. These data include: 

  • Environmental risk assessment data for human and veterinary medicinal products
  • Non-clinical safety data for human medicines
  • Data related to establishment of maximum residue limits for veterinary medicines

To EEA, EMA will provide available data on 'early warning signals' from its medicine evaluation activities.

Share this page